Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha4 integrin in islet allograft rejection.

M D Stegall1, P G Dean, D Ninova

  • 1The Transplantation Research Laboratory, Department of Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

Transplantation
|July 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C-kit-derived CD11b<sup>+</sup> cells are critical for cardiac allograft prolongation by autologous C-kit<sup>+</sup> progenitor cells.

Cellular immunology·2019
Same author

Routine Stenting of Extravesical Ureteroneocystostomy in Kidney Transplantation: A Systematic Review and Meta-analysis.

Transplantation proceedings·2018
Same author

Aging phenotype(s) in kidneys of diabetic mice are p66ShcA dependent.

American journal of physiology. Renal physiology·2018
Same author

Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.

Transplantation proceedings·2017
Same author

Renal Allograft Histology at 10 Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017

Blocking alpha4 integrin interactions with its ligands, vascular cell adhesion molecule-1 (VCAM-1) and fibronectin, significantly improves islet allograft survival. This approach may offer novel immunosuppression strategies for preventing organ transplant rejection.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Molecular Medicine

Background:

  • Adhesion molecules play a crucial role in allograft rejection processes.
  • Understanding these interactions is key to developing new immunosuppression strategies.

Purpose of the Study:

  • To investigate the impact of blocking alpha4 integrin interactions with VCAM-1 and fibronectin on islet allograft survival.
  • To evaluate the therapeutic potential of targeting alpha4 integrin pathways in transplantation.

Main Methods:

  • Islet transplantation in streptozotocin-induced diabetic mice.
  • Treatment with antibodies against alpha4 integrin and VCAM-1, and a CS1-peptide.
  • Assessment of graft function via blood glucose levels and immunohistochemical analysis.

Related Experiment Videos

Main Results:

  • Long-term survival of islet allografts was achieved with anti-alpha4 integrin antibody, anti-VCAM-1 antibody, and CS1-peptide treatment.
  • Anti-alpha4 integrin antibody and CS1-peptide abolished cellular infiltration into the graft.
  • Anti-VCAM-1 treatment showed peri-islet infiltration of activated T cells, despite graft survival.

Conclusions:

  • Alpha4 integrin is essential for allograft rejection.
  • Targeting alpha4 integrin or its ligands (VCAM-1, fibronectin) can prolong allograft survival.
  • Blocking alpha4 integrin interactions presents a promising avenue for novel immunosuppressive therapies.